These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 10827390)

  • 21. Reliability and prognostic value of traditional signs and symptoms in outpatients with congestive heart failure.
    Rohde LE; Beck-da-Silva L; Goldraich L; Grazziotin TC; Palombini DV; Polanczyk CA; Clausell N
    Can J Cardiol; 2004 May; 20(7):697-702. PubMed ID: 15197422
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Diagnostic improvement of renal ultrasonography in humans after i.v. injection of perflenapent emulsion.
    Correas JM; Menassa L; Hélénon O; Méjean A; Boyer JC; Mamzer MF; Moreau JF
    Acad Radiol; 1998 Apr; 5 Suppl 1():S185-8; discussion S199. PubMed ID: 9561077
    [No Abstract]   [Full Text] [Related]  

  • 23. A prospective double-blind randomized placebo-controlled clinical trial to evaluate the safety and efficacy of spironolactone in patients with advanced congestive heart failure on continuous ambulatory peritoneal dialysis.
    Taheri S; Mortazavi M; Pourmoghadas A; Seyrafian S; Alipour Z; Karimi S
    Saudi J Kidney Dis Transpl; 2012 May; 23(3):507-12. PubMed ID: 22569436
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of once-daily fluticasone furoate/vilanterol on 24-hour pulmonary function in patients with chronic obstructive pulmonary disease: a randomized, three-way, incomplete block, crossover study.
    Boscia JA; Pudi KK; Zvarich MT; Sanford L; Siederer SK; Crim C
    Clin Ther; 2012 Aug; 34(8):1655-66.e5. PubMed ID: 22789766
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Symptoms, comorbidities, and health care in advanced chronic obstructive pulmonary disease or chronic heart failure.
    Janssen DJ; Spruit MA; Uszko-Lencer NH; Schols JM; Wouters EF
    J Palliat Med; 2011 Jun; 14(6):735-43. PubMed ID: 21510771
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Safety and efficiency of Echogen. Transthoracic echocardiography study].
    Espinola-Zavaleta N; Yánac-Chávez P; Vargas-Barrón J; Romero-Cárdenas A; Roldán-Gómez J
    Gac Med Mex; 2001; 137(3):203-8. PubMed ID: 11432089
    [TBL] [Abstract][Full Text] [Related]  

  • 27. More Impaired Dynamic Ventilatory Muscle Oxygenation in Congestive Heart Failure than in Chronic Obstructive Pulmonary Disease.
    Chuang ML; Lin IF; Hsieh MJ
    J Clin Med; 2019 Oct; 8(10):. PubMed ID: 31591369
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety, tolerability and efficacy of indacaterol, a novel once-daily beta(2)-agonist, in patients with COPD: a 28-day randomised, placebo controlled clinical trial.
    Beier J; Chanez P; Martinot JB; Schreurs AJ; Tkácová R; Bao W; Jack D; Higgins M
    Pulm Pharmacol Ther; 2007; 20(6):740-9. PubMed ID: 17088091
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of high-dose furosemide and small-volume hypertonic saline solution infusion in comparison with a high dose of furosemide as bolus in refractory congestive heart failure: long-term effects.
    Licata G; Di Pasquale P; Parrinello G; Cardinale A; Scandurra A; Follone G; Argano C; Tuttolomondo A; Paterna S
    Am Heart J; 2003 Mar; 145(3):459-66. PubMed ID: 12660669
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term safety of glycopyrrolate: A randomized study in patients with moderate-to-severe COPD (GEM3).
    Mahler DA; Gifford AH; Satti A; Jessop N; Eckert JH; D'Andrea P; Mota F; Banerjee R
    Respir Med; 2016 Jun; 115():39-45. PubMed ID: 27215502
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Oxygen uptake efficiency slope and chronotropic incompetence in chronic heart failure and chronic obstructive pulmonary disease.
    Terziyski KV; Marinov BI; Aliman OI; St Kostianev S
    Folia Med (Plovdiv); 2009; 51(4):18-24. PubMed ID: 20232653
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cardiac safety profile of nebulized formoterol in adults with COPD: a 12-week, multicenter, randomized, double- blind, double-dummy, placebo- and active-controlled trial.
    Nelson HS; Gross NJ; Levine B; Kerwin EM; Rinehart M; Denis-Mize K;
    Clin Ther; 2007 Oct; 29(10):2167-78. PubMed ID: 18042473
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cardiovascular magnetic resonance imaging to identify left-sided chronic heart failure in stable patients with chronic obstructive pulmonary disease.
    Rutten FH; Vonken EJ; Cramer MJ; Moons KG; Velthuis BB; Prakken NH; Lammers JW; Grobbee DE; Mali WP; Hoes AW
    Am Heart J; 2008 Sep; 156(3):506-12. PubMed ID: 18760133
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Enhanced left ventricular endocardial border delineation with an intravenous injection of SonoVue, a new echocardiographic contrast agent: A European multicenter study.
    Senior R; Andersson O; Caidahl K; Carlens P; Herregods MC; Jenni R; Kenny A; Melcher A; Svedenhag J; Vanoverschelde JL; Wandt B; Widgren BR; Williams G; Guerret P; la Rosee K; Agati L; Bezante G
    Echocardiography; 2000 Nov; 17(8):705-11. PubMed ID: 11153016
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Unrecognised ventricular dysfunction in COPD.
    Macchia A; Rodriguez Moncalvo JJ; Kleinert M; Comignani PD; Gimeno G; Arakaki D; Laffaye N; Fuselli JJ; Massolin HP; Gambarte J; Romero M; Tognoni G
    Eur Respir J; 2012 Jan; 39(1):51-8. PubMed ID: 21700606
    [TBL] [Abstract][Full Text] [Related]  

  • 36. COPD in chronic heart failure: less common than previously thought?
    Minasian AG; van den Elshout FJ; Dekhuijzen PN; Vos PJ; Willems FF; van den Bergh PJ; Heijdra YF
    Heart Lung; 2013; 42(5):365-71. PubMed ID: 23998385
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluating the safety of mibefradil, a selective T-type calcium antagonist, in patients with chronic congestive heart failure.
    van der Vring JA; Bernink PJ; van der Wall EE; van Velhuisen DJ; Braun S; Kobrin I
    Clin Ther; 1996; 18(6):1191-206. PubMed ID: 9001836
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Differing susceptibility of echocardiographic contrast agents to adverse effects of biologic factors: multicenter, videodensitometric comparison of octafluoropropane-filled microspheres with air-filled microspheres for left ventricular opacification.
    Hausnerova E; Gottdiener JS; Gould JJ; Pezzullo JC; Callahan JD; Cohen JL; Bruns DE; Kuvelas MT; West HE; Dittrich HC
    J Am Soc Echocardiogr; 1999 Nov; 12(11):957-66. PubMed ID: 10552357
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trials.
    Franciosi LG; Diamant Z; Banner KH; Zuiker R; Morelli N; Kamerling IM; de Kam ML; Burggraaf J; Cohen AF; Cazzola M; Calzetta L; Singh D; Spina D; Walker MJ; Page CP
    Lancet Respir Med; 2013 Nov; 1(9):714-27. PubMed ID: 24429275
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase I clinical trials of MRX-115. A new ultrasound contrast agent.
    Fritz TA; Unger EC; Sutherland G; Sahn D
    Invest Radiol; 1997 Dec; 32(12):735-40. PubMed ID: 9406013
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.